iBio, Inc., a preclinical stage biotechnology company, develops artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc., was incorporated in 2008 and is headquartered in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-12 |
2024-09 |
-0.46 |
N/A |
N/A |
N/A |
2024-09-25 |
2024-06 |
-0.46 |
N/A |
N/A |
N/A |
2024-05-13 |
2024-03 |
0 |
-0.71 |
N/A |
N/A |
2024-02-09 |
2023-12 |
0 |
-2.42 |
N/A |
N/A |
2023-11-14 |
2023-09 |
0 |
-4.2 |
N/A |
N/A |
2023-10-10 |
2023-06 |
0 |
N/A |
N/A |
N/A |
Date |
Name |
Relation |
Quantity |
Description |
2023-10-31 |
BRENNER MARTIN |
Chief Executive Officer |
182.50K |
Sale |
2023-03-30 |
DURAN FELIPE |
Chief Financial Officer |
39.63K |
Stock Award(Grant) |
2022-11-10 |
LUTZ ROBERT MATTHEW |
Chief Financial Officer |
102.17K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
512.28K |
312.49K |
1.86% |
2023-06-29 |
Avantax Planning Partners, Inc. |
155.00K |
94.55K |
0.56% |
2023-06-29 |
Blackrock Inc. |
137.94K |
84.14K |
0.50% |
2023-06-29 |
Bank Of New York Mellon Corporation |
87.47K |
53.36K |
0.32% |
2023-06-29 |
Geode Capital Management, LLC |
76.29K |
46.53K |
0.28% |
2023-06-29 |
Renaissance Technologies, LLC |
46.10K |
28.12K |
0.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
336.21K |
205.09K |
1.22% |
2023-06-29 |
Vanguard Extended Market Index Fund |
165.75K |
101.11K |
0.60% |
2023-05-30 |
Fidelity Extended Market Index Fund |
46.85K |
32.80K |
0.17% |
2023-05-30 |
Fidelity Total Market Index Fund |
13.73K |
9.61K |
0.05% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
9.49K |
6.64K |
0.03% |
2023-06-29 |
Vanguard Institutional Index-Inst Total Stock Market Ind |
7.28K |
4.44K |
0.03% |
Split |
Date |
1 : 20 |
2023-11-29 |
1 : 25 |
2022-10-10 |
1 : 10 |
2018-06-11 |